Trials / Not Yet Recruiting
Not Yet RecruitingNCT07501702
A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a Long-term Extension of Povetacicept in Adults With Generalized Myasthenia Gravis
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Vertex Pharmaceuticals Incorporated · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the pharmacodynamic (PD) effect, safety, and tolerability of Povetacicept in participants with generalized myasthenia gravis (gMG).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Povetacicept | Solution for Subcutaneous Injection. |
| DRUG | Placebo | Solution for Subcutaneous Injection. |
Timeline
- Start date
- 2026-04-16
- Primary completion
- 2029-03-02
- Completion
- 2029-03-02
- First posted
- 2026-03-30
- Last updated
- 2026-03-30
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07501702. Inclusion in this directory is not an endorsement.